Pipeline

Small-molecule targeted therapies for infectious diseases and oncology. Our 11 programmes cover the full path from drug discovery to market; Mprosevir® (WPV01) was conditionally approved by China’s NMPA on 29 July 2026.

01 / Marketed

Mprosevir®

WPV01 · iscartrelvir hydrochloride tablets · Iscartrelvir

Target and mechanism: A SARS-CoV-2 main protease 3CLpro inhibitor that binds the target non-covalently, with a novel scaffold.
Origin: Discovered through DNA-encoded library (DEL) screening — the first approved drug worldwide to originate from DEL. Oral monotherapy, no ritonavir booster required.
Approval: Conditionally approved by the NMPA on 29 July 2026 for adults with mild to moderate COVID-19.

3CLpro surface (catalytic core / domain III)Mprosevir® (WPV01)

Note: PDB 7EN8 co-crystal structure; surface generated from experimental coordinates, not a docking model.

Coronaviruses andrespiratory viruses

Our antiviral pipeline currently focuses on broad-spectrum small-molecule drugs against coronaviruses, covering COVID-19, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).

Compound NameTherapeutic Area

01Drug Discovery

02Drug Optimization

03Preclinical

04Phase 1

05Phase 2

06Phase 3

07Marketed

WPV01
COVID-19 · 3CLpro
07 / 07 · Marketed
WPV02
Infectious diseases · 3CLpro
04 / 07 · Phase 1
WPV03
Infectious diseases · RdRp
02 / 07 · Drug Optimization

Resistance mechanismsand targeted intervention

Our oncology pipeline starts from the mechanisms that generate drug resistance in cancer cells. We explore new strategies for anticancer drug design and develop molecules that either block the emergence of resistance or kill drug-resistant cancer cells.